⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,692.59
+0.43%
Nasdaq 100
29,538.41
+1.20%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.15
+1.41%
NYSE:TSM
$420.27
+1.86%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,140.75
−0.59%
Brent
$109.32
−0.45%
BTC
$81,803.72
−0.26%
ETH
$2,394.06
−0.55%
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,692.59
+0.43%
Nasdaq 100
29,538.41
+1.20%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.15
+1.41%
NYSE:TSM
$420.27
+1.86%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,140.75
−0.59%
Brent
$109.32
−0.45%
BTC
$81,803.72
−0.26%
ETH
$2,394.06
−0.55%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Bristol-Myers Squibb Co · News · TradingHolo
Markets
›
United States
› NYSE
› BMY
B
Bristol-Myers Squibb Co
NYSE:BMY
Healthcare
CBOE:SPESG
STOXX:EDD24BP
$59.13
−1.05%
Live
In session · ≈
AED 217.14
· Market cap
$120.78B
· Next earnings
Thu 29 Oct
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
BMY news
Headlines tagged to this company
RE
Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Reuters · 4 d ago
RE
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Reuters · 4 d ago
DO
Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs — WSJ
Dow Jones Newswires · 4 d ago
RE
Pharma sector doubles down on AI to slash costs, timelines
Reuters · 5 d ago
DO
Bristol-Myers Squibb Price Target Cut to $60.00/Share From $65.00 by Wells Fargo
Dow Jones Newswires · 6 d ago
ST
BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses
Stocktwits · 7 d ago
SE
Bristol down as Street reacts to admilparant results in IPF
Seeking Alpha · 7 d ago
DO
Bristol Myers Stock Is Rising on a Double Dose of Good News — Barrons.com
Dow Jones Newswires · 7 d ago
RE
Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS
Reuters · 7 d ago
DO
Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis
Dow Jones Newswires · 7 d ago
RE
Bristol Myers cancer therapy meets main goal in late-stage study
Reuters · 7 d ago
SE
Bristol Myers jumps as two late-stage trials deliver positive results
Seeking Alpha · 7 d ago
RE
Bristol Myers' drug improves lung function in late-stage trial
Reuters · 7 d ago
RE
Bristol Myers' lung disease drug meets main goal in late-stage trial
Reuters · 7 d ago
RE
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Reuters · 7 d ago
SE
Notable healthcare headlines for the week: Novavax, Moderna and Becton Dickinson in focus
Seeking Alpha · 8 d ago
SE
Hospital group files lawsuit to stop 340B rebate pilot again
Seeking Alpha · 9 d ago
SE
Bristol Myers posts late-stage trial win for multiple myeloma therapy Zenbexus
Seeking Alpha · 11 d ago
More news →